PHARNEXT-SA
3.11.2016 08:03:46 CET | Business Wire | Press release
Regulatory News:
Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA), a French biopharmaceuticals company developing an advanced portfolio of products in the field of neurodegenerative diseases, announces today its participation at the Jefferies 2016 London Healthcare Conference taking place November 16-17 at the Waldorf Hotel in London, UK.
This Conference is the largest healthcare meeting in Europe dedicated to companies from around the world: biotechnologies, pharmaceuticals, generics, medtechs and healthcare services. Last year, the Jefferies conference hosted over 300 participating companies, 1,200 attendees and 3,700 B2B and investor meetings.
ABOUT PHARNEXT
Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPIE®. Pharnext identifies and develops synergetic combinations of drugs that are already being used for other diseases. These PLEOMEDICAMENT® are developed at new lower doses and repositioned into new indications. The PLEOMEDICAMENT® offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted. The Company is supported by a world-class scientific team.
The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).
For more information, visit www.pharnext.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20161103005151/en/
Contact:
Pharnext
Pierre Schwich, +33 (0)1 41 09 22 30
Directeur
Financier
investors@pharnext.com
or
NewCap
Relations
Investisseurs
Julie Coulot, +33 (0)1 44 71 20 40
pharnext@newcap.eu
or
Media
Relations (Europe)
Alize RP
Caroline Carmagnol
Margaux
Pronost
+33 (0)1 44 54 36 64
pharnext@alizerp.com
or
Media
Relations (US)
Russo Partners
Tony Russo, Ph.D.
Matt
Middleman, M.D.
+1 212-845-4272
matt.middleman@russopartnersllc.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Elects Kathleen Tregoning to Board of Directors28.5.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to its Board of Directors at the annual general meeting of shareholders. Ms. Tregoning is expected to serve on the Compensation and Leadership Development Committee and the Nominating and Corporate Governance Committee. She brings extensive experience guiding biopharmaceutical companies through periods of growth and transformation, with expertise spanning corporate strategy, external affairs, public policy and patient access. “With two successful Phase 3 trials meeting the primary endpoint, a transformative clinical profile for COMP360, and a rolling NDA submission and review now underway, Compass is strongly positioned to make our goal of securing an FDA approval a reality. Compass is entering a stage where experience in external engagement, public policy, and patient access matters more
Alzprotect Announces FDA Clearance of IND for AZP2006 (Ezeprogind®) in Progressive Supranuclear Palsy (PSP)28.5.2026 12:28:00 CEST | Press release
IND enables initiation of U.S. clinical development in PSP Alzprotect today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for AZP2006 (Ezeprogind®) for the treatment of Progressive Supranuclear Palsy (PSP). FDA clearance permits the Company to begin clinical development of AZP2006 in the United States. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526387210/en/ “FDA IND clearance is a pivotal step in our PSP program,” said Philippe Verwaerde, PhD, President & Chief science Officer. “We can now expand our clinical efforts in the U.S. to evaluate AZP2006’s potential to address PSP, a severe neurodegenerative disease with no approved disease-modifying therapies.” Dr. Artin Karapet, Chief Medical Officer, commented: “The FDA’s clearance of our IND for AZP2006 is a pivotal milestone, aligning U.S. and European regulatory pathways and enabling th
LMR by IFF Inaugurates New Experimental Field in Grasse28.5.2026 11:00:00 CEST | Press release
Furthering IFF’s leadership in natural ingredients for perfumery. LMR Naturals by IFF—a global leader in natural ingredients for perfumery, cosmetics and flavors—today inaugurated its new experimental field, Domaine des Naturels LMR. The field is dedicated to advancing research in natural ingredients, preserving Grasse’s agricultural heritage and expanding education in naturals. The inauguration, attended by Grasse Mayor Jérôme Viaud, a long-standing supporter of the perfume industry, underscores IFF and LMR’s ongoing commitment to the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527694524/en/ At Domaine des Naturels LMR, R&D experts research new natural species, variety breeding, cultivation methods and production techniques. “This inauguration reflects over two decades of continuous investment in Grasse and in naturals,” said Ana Paula Mendonça, president, Scent, IFF. “With Domaine des Naturels LMR, we are bri
Reply Expands Prebuilt AI Apps With New Production-Ready Applications to Accelerate Enterprise AI Adoption28.5.2026 10:00:00 CEST | Press release
Reply[EXM, STAR: REY] today released a new set of Prebuilt AI Apps: ready-to-use agentic applications designed to drive efficiency and business growth by accelerating the integration of AI into enterprise processes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528283268/en/ Prebuilt AI Apps are ready-to-use agentic applications designed to accelerate the integration of AI into enterprise processes, driving efficiency and supporting business growth. In developing the Prebuilt AI Apps, Reply has identified key areas within enterprise processes where AI can create tangible operational value and turned them intoreusable assets, combining deep process knowledge, curated datasets, domain ontologies and reusable agentic flows in robust, secure and production-ready solutions. Each application can be further customised and extended through integration with enterprise systems, internal data and knowledge bases, while maintaining
Klarna Partners With Arrive for Parking in 15 Markets28.5.2026 09:56:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has partnered with Arrive, a leading global mobility platform, to bring seamless and flexible payment options to millions of consumers across 15 markets. Through the partnership, drivers will be able to pay for parking using Klarna’s Pay in Full, which will be available directly in Arrive’s EasyPark app, ensuring payments can be made instantly. This provides consumers with more flexibility and control over their everyday spending, and builds on Klarna's growing presence in everyday spending and saving, where consumers increasingly use Klarna for recurring, low-friction purchases alongside savings products like Klarna Balance. Arrive, formerly EasyPark Group, operates one of the world’s largest digital parking networks, facilitating high frequency payments across millions of spots in more than 20,000 cities and 90 countries. By providing the digital infrastructure that helps individuals and decision-makers make smarter urba
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom